A Solution For Elan: It Strikes A Deal With J&J On Key Alzheimer's Assets
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J gets to build its fledgling Alzheimer's program, while Elan gets cash to strengthen its balance sheet, plus a new minority shareholder and strong global partner.
You may also be interested in...
Elan’s Martin Aims To Set The Record Straight About Recent Buying Spree
Changes at the Irish company have sparked a swath of media speculation and analyst interest. Elan CEO Kelly Martin used a recent fireside chat in New York to paint a clearer picture of what is going on at the company and the rationale behind its recently proposed M&A.
Elan Prepares For A Buying Spree Now That Biogen Has Taken Over Tysabri
Biogen Idec announced Feb.6 that it will pay $3.25 billion to its partner Elan for full rights to the multiple sclerosis drug Tysabri. The deal was not a surprise to Biogen investors, but it leaves Elan with a war chest of cash and virtually no commercial assets.
Elan Unit’s Acquisition Brings Diversification, Cash Flow, To Alkermes
Alkermes Inc's acquisition of Elan Corp.'s Elan Drug Technology, announced May 9, more than doubles the revenues of one of the biopharma industry's most successful reformulation companies, and provides it with additional cash flow it needs to pursue a slate of innovative compounds it is developing.